Tigulixostat
As of the edition of 20 October 2026, Tigulixostat is a small molecule: in active development; acts on XDH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 10, 0 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| XDH | Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | P47989 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| LG Life Sciences | Lead sponsor of trials | 2011 to now |
| LG Chem | Lead sponsor of trials | 2019 to now |
| Innovent Biologics Technology | Lead sponsor of trials | 2026 to now |